Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine by Wohl, D. et al.
Vol.:(0123456789)
The Patient - Patient-Centered Outcomes Research (2018) 11:561–573 
https://doi.org/10.1007/s40271-018-0322-8
ORIGINAL RESEARCH ARTICLE
Patient‑Reported Symptoms Over 48 Weeks Among Participants 
in Randomized, Double‑Blind, Phase III Non‑inferiority Trials of Adults 
with HIV on Co‑formulated Bictegravir, Emtricitabine, and Tenofovir 
Alafenamide versus Co‑formulated Abacavir, Dolutegravir, 
and Lamivudine
David Wohl1 · Amanda Clarke2 · Franco Maggiolo3 · Will Garner4 · Marianne Laouri4 · Hal Martin4 · Erin Quirk4
Published online: 29 June 2018 
© The Author(s) 2018
Abstract
Background Integrase strand transfer inhibitors (INSTIs) are recommended for first-line antiretroviral therapy in combination 
with two nucleos(t)ide reverse transcriptase inhibitors. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide 
(B/F/TAF), a novel, INSTI-based regimen, is currently approved in the US and EU for the treatment of HIV-1 infection 
and recommended as first-line treatment in current guidelines. In our current analysis, we aimed to determine changes in 
patient-reported symptoms over time among HIV-1-infected adults who initiated or switched to B/F/TAF versus another 
INSTI-based regimen, co-formulated abacavir, dolutegravir, and lamivudine (ABC/DTG/3TC).
Methods A planned secondary analysis of patient-reported outcomes was conducted for two double-blind, randomized, 
phase III studies in HIV-1-infected adults comparing B/F/TAF with ABC/DTG/3TC: one in treatment-naïve individuals 
(GS-US-380-1489, ClinicalTrials.gov NCT02607930) and the other in virologically suppressed participants (GS-US-380-
1844, ClinicalTrials.gov NCT02603120). In both studies, the HIV symptoms distress module (HIV-SI) was administered at 
baseline (BL) and weeks 4, 12, and 48. Responses to each of the 20 items were dichotomized as bothersome or not bother-
some. Treatment differences were assessed using unadjusted and adjusted logistic regression models (adjusted for BL HIV-SI 
count, age, sex, BL Veterans Aging Cohort Study [VACS] Index, medical history of serious mental illness, BL Short Form 
[SF]-36 Physical Component Summary [PCS], BL SF-36 Mental Component Summary [MCS], and, for virologically sup-
pressed participants only, years since HIV diagnosis). We conducted longitudinal modeling of bothersome symptoms using 
a generalized mixed model including treatment, time, time-by-treatment, and additional covariates from the adjusted logistic 
regression model as described above. The Pittsburgh Sleep Quality Index (PSQI) was administered at the same frequency 
as the HIV-SI, and the total score was dichotomized as good or poor sleep quality. Similar models to those used for HIV-SI 
were applied, using BL sleep quality and BL SF-36 MCS as covariates. Statistical significance was assessed using p < 0.05.
Results Across both studies, bothersome symptoms were reported by fewer participants on B/F/TAF than those on ABC/
DTG/3TC. In treatment-naïve adults, fatigue/loss of energy, nausea/vomiting, dizzy/lightheadedness, and difficulty sleeping 
were reported significantly less with B/F/TAF at two or more time points. Fatigue and nausea were also significantly less 
common for those receiving B/F/TAF in longitudinal models. In virologically suppressed participants, nausea/vomiting, sad/
down/depressed, nervous/anxious, and poor sleep quality (from the PSQI) were reported significantly less with B/F/TAF at 
two or more time points, as well as in longitudinal models.
Conclusions B/F/TAF was associated with lower prevalence of bothersome symptoms than ABC/DTG/3TC in both treatment-
naïve and virologically suppressed adults.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-018-0322-8) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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Key points for decision makers 
As the efficacy of triple-therapy antiretroviral regimens 
remains consistently high, patient well-being (e.g., 
patient-reported outcomes [PROs]) has become an 
important differentiator between regimens.
We evaluated PROs in two studies comparing co-
formulated bictegravir, emtricitabine, and tenofovir 
alafenamide (B/F/TAF) with co-formulated abacavir, 
dolutegravir, and lamivudine (ABC/DTG/3TC), where 
treatment differences were noted if prevalence was statis-
tically significantly different at two or more time points 
in the adjusted logistic regression model or at one time 
point in the adjusted logistic regression model and in the 
longitudinal model.
Among treatment-naïve participants, initiating B/F/
TAF was associated with lower prevalence of fatigue/
loss of energy, dizzy/lightheadedness, nausea/vomiting, 
difficulty sleeping, and loss of appetite compared with 
ABC/DTG/3TC.
For virologically suppressed participants, switching to 
B/F/TAF was associated with lower prevalence of dizzy/
lightheadedness, nausea/vomiting, sad/down/depressed, 
nervous/anxious, difficulty sleeping, and loss of appetite 
compared with remaining on ABC/DTG/3TC.
In both patient populations, no symptom had a greater 
prevalence with B/F/TAF compared with ABC/
DTG/3TC.
1 Introduction
Over the past decade, antiretroviral treatments for HIV infec-
tion have demonstrated high potency, yielding viral suppres-
sion rates above 90%. Integrase strand inhibitors (INSTIs; 
e.g., bictegravir, dolutegravir, elvitegravir, and raltegravir) 
in combination with two nucleos(t)ide reverse transcriptase 
inhibitors (NRTIs) are currently recommended as initial 
treatment for HIV in many international guidelines [1–3]. 
As the success of antiretroviral therapy largely depends on 
patient adherence, fixed-dose combinations (FDCs) have 
emerged as preferred treatment regimens and are associated 
with less treatment failure [4]. The impact of FDCs on an 
individual’s overall health, including sense of wellbeing, has 
also become an important consideration for clinicians when 
prescribing HIV treatment.
Bictegravir (BIC, B) and dolutegravir (DTG) are INSTIs 
that do not require the co-administration of a pharmaco-
enhancer (i.e., cobicistat or ritonavir) [5]. Both have been 
co-formulated with NRTIs as FDCs: BIC with emtricit-
abine (FTC, F) and tenofovir alafenamide (TAF) as B/F/
TAF and DTG with abacavir (ABC) and lamivudine (3TC) 
as ABC/DTG/3TC. ABC/DTG/3TC is currently recom-
mended as first-line antiretroviral therapy (ART) [1–3] and 
represents a logical, standard-of-care comparator for new 
INSTI-based FDCs. ABC requires HLA B*5701 testing 
prior to use, and the ABC/DTG/3TC co-formulation does 
not provide adequate treatment for hepatitis B in individu-
als co-infected with HIV [1, 3]. The US AIDS Clinical Tri-
als Group (ACTG) 5202 study found a significantly shorter 
time to treatment modification and a greater incidence of 
nausea with the ABC/3TC NRTI backbone than with FTC/
tenofovir disoproxil fumarate [6]. Furthermore, some reports 
have emerged showing associations between DTG and neu-
ropsychiatric adverse events, while others have not [7–13].
BIC has a high barrier to resistance and a low potential 
for drug–drug interactions [14]. In four studies reported to 
date (two in treatment-naïve adults and two in virologically 
suppressed participants), the B/F/TAF FDC has shown simi-
lar high efficacy and tolerability to standard-of-care compar-
ators, with no treatment-emergent resistance [15–18]. The 
primary outcome of all studies demonstrated non-inferiority 
of B/F/TAF to either ABC/DTG/3TC, DTG + F/TAF, or 
boosted protease-inhibitor (PI) regimens. Switching to B/F/
TAF from ABC/DTG/3TC specifically has the potential to 
maintain high rates of suppression while avoiding limita-
tions of ABC, such as potential cardiovascular risk [19–21], 
as well as central nervous system adverse effects and dis-
continuations that have been reported more frequently with 
DTG in clinical practice and cohort studies than in published 
results of clinical trials [9, 22, 23]. B/F/TAF also provides 
two NtRTIs with hepatitis B activity and the tablet is less 
than half the size of co-formulated ABC/DTG/3TC, which 
may improve acceptability amongst individuals and ability 
to use in pediatric populations [24–26, data on file]. B/F/
TAF has been approved in the US and EU for treatment of 
HIV-1 infection in adults and adolescents and is now also 
recommended as first-line ART in current treatment guide-
lines [3].
Health-related quality-of-life (HRQL) outcomes have 
long been regarded as important in the evaluation and dif-
ferentiation of treatment strategies [27]. To better understand 
the two FDCs of B/F/TAF and ABC/DTG/3TC, patient-
reported outcomes (PROs), including one specifically 
designed for HIV-1-infected participants, were measured 
in both treatment-naïve and HIV-1-suppressed adults using 
previously validated questionnaires in comparative trials of 
these regimens. For treatment-naïve individuals, characteri-
zation of PROs provided the opportunity to assess the two 
regimens directly after initiating treatment. Comparison of 
the treatments in virologically suppressed individuals who 
were presumably tolerating their baseline regimen of ABC/
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DTG/3TC provided further delineation of how changes to 
medication may alter quality-of-life outcomes. We aimed to 
achieve a better understanding of the relationship between 
these treatments and bothersome HIV symptoms and/or 
adverse events that impact adherence and persistence.
2  Methods
2.1  Study Design
Study design and participant recruitment for both trials have 
been previously described [15, 17]. Briefly, both were inter-
national, double-blind, randomized, phase III studies that 
compared the efficacy and safety of B/F/TAF (50/200/25 mg) 
with ABC/DTG/3TC (600/50/300 mg) in adults who were 
either treatment naïve (GS-US-380-1489, ClinicalTrials.gov 
NCT02607930) or virologically suppressed (GS-US-380-
1844, ClinicalTrials.gov NCT02603120). For both studies, 
post-baseline study visits occurred at weeks 4, 8, 12, 24, 
36, and 48, with PRO measures administered at baseline 
and weeks 4, 12, and 48. Participants and investigators were 
masked to treatment allocation in both studies. Translated 
versions of all PRO tools were administered in the partici-
pant’s preferred language.
2.2  Baseline Demographics and Characteristics
Demographics (sex, age, race, and ethnicity) and clinical 
characteristics (serious mental illness, CD4 cell count, 
asymptomatic HIV infection status, years since HIV diag-
nosis, years since first antiretroviral therapy use (GS-US-
380-1844 only), the Veterans Aging Cohort Study [VACS] 
Risk Index, and Fibrosis [FIB]-4 score) were collected or 
calculated. Serious mental illness was defined as a diagnos-
tic history entered as existing medical history at the time of 
study entry of one or more of the following conditions based 
on medical chart review: major depression, anxiety, schizo-
phrenia, bipolar disorder, post-traumatic stress disorder, or 
other serious mental illness. The VACS Index was calculated 
to quantify the overall mortality risk associated with HIV 
and is a summary score based on age, CD4 count, HIV-1 
RNA, the FIB-4 score, creatinine, and coinfection with viral 
hepatitis C infection, and is used to predict all-cause and 
cause-specific mortality and other outcomes in those living 
with HIV infection [28]. The FIB-4 score, computed using 
age, platelet count, and aspartate and alanine transaminase 
values, provides an estimate of the degree of liver fibrosis in 
HIV and hepatitis C virus co-infected patients [29].
2.3  Patient‑Reported Outcomes (PROs)
2.3.1  HIV Symptom Distress Module (HIV‑Symptom Index 
[HIV‑SI])
The dependent variable in this study was the HIV-Symptom 
Index (HIV-SI). The HIV-SI is a validated PRO instrument 
that assesses the burden of 20 common symptoms associ-
ated with HIV treatment or disease [30]. The instrument 
is considered to be the gold standard in contemporary 
HIV symptom research [31]. Respondents are asked about 
their experience with each of 20 symptoms during the past 
4 weeks using a 5-point, Likert-type scale. Response options 
and scores are as follows: (0) “I don’t have this symptom;” 
(1) “I have this symptom and it doesn’t bother me;” (2) “I 
have this symptom and it bothers me a little;” (3) “I have this 
symptom and it bothers me;” (4) “I have this symptom and 
it bothers me a lot.”
The 20 symptoms comprising the HIV-SI are fatigue/
loss of energy, difficulty sleeping, nervous/anxious, diar-
rhea/loose bowels, changes in body composition, feeling 
sad/down/depressed, bloating/pain/gas in stomach, muscle 
aches/joint pain, problems with sex, trouble remember-
ing, headaches, pain/numbness/tingling in hands/feet, skin 
problems/rash/itching, cough/trouble breathing, fever/chills/
sweats, dizzy/lightheadedness, weight loss/wasting, nausea/
vomiting, hair loss/changes, and loss of appetite/food taste.
Consistent with prior analyses by Edelman and col-
leagues [32], we dichotomized symptoms into not bother-
some (scores of 0 or 1) or bothersome (scores of 2, 3 and 
4). The overall bothersome symptom count at baseline was 
generated by counting the number of individual symptoms 
scored as bothersome and used as a covariate in regression 
analyses and longitudinal modeling.
2.3.2  Other Descriptive PRO Measures
Other PRO instruments used to describe HRQL included 
the Short Form (SF)-36, the Pittsburgh Sleep Quality Index 
(PSQI), and the Work Productivity and Activity Impairment 
(WPAI)—General Health questionnaire. The SF-36 is an 
instrument supported by extensive evidence of good psy-
chometric properties in a range of therapeutic areas [33, 34], 
including HIV-infected individuals [35]. The score ranges 
from 0 to 100, with a higher score indicating better function-
ing. For our analyses, we further transformed the physical 
component summary (PCS) and mental component sum-
mary (MCS) scores into norm-based scoring, with a mean 
of 50 and a standard deviation of 10 using the QualityMetric 
Health Outcomes™ Scoring Software 4.5 (QualityMetric 
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Incorporated [now part of OPTUM], Lincoln, RI, USA). The 
PSQI is a validated, 19-item instrument that assesses sleep 
quality and disturbances over a 1-month time interval; the 
total score is dichotomized into poor or good sleep quality 
[36]. The total score ranges from 0 to 21, with a lower score 
indicating better sleep quality. The WPAI—General Health 
questionnaire is a 6-item tool that measures health-related, 
work productivity loss for the employed population as per 
the amount of absenteeism, presenteeism, and daily activity 
impairment attributable to general health [37]. For each of 
these measures, a lower value indicates better quality of life 
outcome. Additionally, the PCS and MCS from SF-36 were 
used as covariates in regression and longitudinal analyses 
of the HIV-SI.
2.4  Statistical Analysis
Analyses were performed using SAS v9.4M3 (SAS Institute, 
Cary, NC, USA). If multiple responses were provided for an 
item on the HIV-SI, the most severe (i.e., largest value) of 
the responses was used.
Baseline demographic and clinical characteristics were 
summarized using descriptive statistics. To determine 
between-treatment comparisons, we used the Fisher exact 
test for categorical data or a 2-sided Wilcoxon rank sum 
test for continuous data. The change from baseline in SF-36 
PCS/MCS scores and WPAI scores were summarized 
using descriptive statistics, and a 2-sided Wilcoxon rank 
sum test was used for between-treatment comparisons. The 
prevalence (i.e., number and percentage of participants) 
of reported poor sleep quality on the PSQI was also sum-
marized, and the Fisher exact test was used for between-
treatment comparison. Unadjusted and adjusted analyses at 
weeks 4, 12, and 48 were performed to evaluate the relation-
ship between treatment assignment and the probability of 
experiencing an HIV-SI symptom, with and without addi-
tional covariates (adjusted and unadjusted, respectively). 
Specifically, HIV-SI symptoms were modeled as binary 
outcomes using a logistic regression. Descriptive variables 
were evaluated for multicollinearity and models were fitted/
tested with independent variables of treatment and a sub-
set of clinical and demographic covariates (selected from a 
larger list of potential demographic and clinical variables). 
The subset of clinical and demographic covariates was 
selected in two steps. First, for each symptom/time point, 
stepwise model selection was used to identify statistically 
significant covariates from all potential covariates (i.e., 
all these baseline demographic and clinical characteristics 
listed in Table 1, baseline HIV-1 RNA, and baseline C4 cell 
counts). Second, all the sixty models (i.e., 20 symptoms × 3 
visits) were reviewed and a single set of covariates were 
selected across all models to ensure easy interpretation and 
simplification of the model. Furthermore, the same model 
was generally used for both studies, with the exception of 
utilizing years since HIV diagnosis in Study 380-1844 only.
Longitudinal modeling was performed using generalized 
mixed-effects models to show symptom patterns over each of 
the four study visits using data from the HIV-SI. The func-
tional form of the change pattern was assessed visually from 
the observed prevalence in each group. Linear and quad-
ratic patterns were tested to determine optimal fit, ultimately 
favoring a linear function. Post-baseline data were modeled 
with baseline values included as a covariate. To assess the 
possibility that the effect of treatment may itself vary over 
time, the models included an interaction between study treat-
ment and time in addition to the indicator of a simple study 
treatment group. Continuous variables were mean centered 
for ease of interpretation and model fit. The fit of each of 
the derived models was compared with a simple unadjusted 
model that included time and study treatment, along with a 
random intercept to account for the longitudinal nature of 
the data. The comparison was based on Bayesian informa-
tion criterion.
Poor sleep quality according to the PSQI was analyzed 
in a similar manner as the HIV-SI, but only used baseline 
sleep quality (good vs poor) and baseline SF-36 MCS as 
covariates.
3  Results
3.1  Baseline Characteristics
Baseline demographics and clinical characteristics were sim-
ilar between treatment groups (Table 1) in each study. Most 
participants were White and male. Participants reported a 
median of three to four bothersome HIV-SI symptoms at 
baseline, with 17–25% reporting no symptoms. Overall, 
there were no significant differences at baseline between 
those assigned B/F/TAF compared with ABC/DTG/3TC in 
any PRO measure (Table 1). Among the items captured by 
the HIV-SI for both treatment-naïve and virologically sup-
pressed adults, the only significant difference between treat-
ment groups was more weight loss/wasting reported at base-
line among those assigned B/F/TAF versus ABC/DTG/3TC 
(18.3 vs 11.3%; p = 0.017) in treatment-naive participants 
(study 380-1489) (Tables 2, 3).
3.2  Changes in PRO Measures from Baseline 
to Week 48
In treatment-naive adults (Study 380-1489), median [IQR] 
SF-36 PCS and MCS scores were comparable between 
the B/F/TAF and ABC/DTG/3TC groups at baseline 
(57.4 [52.6–60.0] vs 56.6 [52.2–59.3], p = 0.18 and 49.0 
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[37.7–55.2] vs 49.5 [40.0–56.3], p = 0.40, respectively). 
Changes from baseline at week 48 in PCS and MCS scores 
were also similar between groups; median (IQR) change 
from baseline in PCS was 0.1 (− 3.3 to 3.1) versus 0.2 (− 2.6 
to 2.8), p = 0.85 and in MCS was 2.3 (− 1.6 to 9.0) versus 
2.1 (− 4.0 to 7.0), p = 0.090. At baseline, 48.1 and 47.6% of 
participants on B/F/TAF and ABC/DTG/3TC, respectively, 
reported poor sleep quality on the PSQI (p = 0.93). At week 
48, the proportion had decreased to 38.7 and 41.5% of par-
ticipants, respectively (p = 0.50). The WPAI questionnaire 
did not show any differences between treatment groups at 
baseline or any post-baseline time point.
In virologically suppressed adults (Study 380-1844), 
median [IQR] SF-36 PCS and MCS scores were comparable 
between the B/F/TAF and ABC/DTG/3TC groups at base-
line (55.5 [50.5–59.1] vs 56.6 [51.0–59.2], p = 0.31 and 51.9 
[44.5–57.5] vs 53.2 [46.6–57.6], p = 0.14, respectively). At 
week 48, median [IQR] PCS and MCS scores were largely 
unchanged from baseline (PCS change: − 0.4 [− 3.6 to 
2.7] vs 0.2 [− 2.3 to 2.7], p = 0.17; MCS change: median 
[IQR]: 0.3 [− 3.0 to 4.6] vs 0.1 [− 3.9 to 3.5], p = 0.13). At 
baseline, 51.9 and 46.1% of adults on B/F/TAF and ABC/
DTG/3TC, respectively, reported poor sleep quality on the 
PSQI (p = 0.19). At week 48, the proportion had decreased 
to 41.8 and 45.7% of individuals, respectively (p = 0.42).
The WPAI questionnaire did not show any differences 
between treatment groups in any of the four measures at 
baseline or any post-baseline time point.
Table 1  Patient-reported baseline demographics and clinical characteristics
Data are reported as median (IQR) or n (%), except for age, which is median (range)
For categorical data, the p value was from the Fisher exact test. For continuous data, p value was from the 2-sided Wilcoxon rank sum test
Subjects with race of ‘Not Permitted’ were excluded from percentage calculations
ABC/DTG/3TC co-formulated abacavir, dolutegravir, and lamivudine, B/F/TAF co-formulated bictegravir, emtricitabine, and tenofovir alafena-
mide, FIB-4 Fibrosis 4 score, GFR glomerular filtration rate, HIV-SI HIV Symptom Index, SF-36 MCS Short Form 36 Mental Composite Score, 
SF-36 PCS Short Form 36 Physical Composite Score, VACS Veterans Aging Cohort Study
a VACS Index is a score from 0 to 164 derived from the patient’s age, CD4 cell count, HIV-1 RNA level, hemoglobin value, platelet count, aspar-
tate and alanine transaminase levels, serum creatinine value, and a positive hepatitis C infection status at one specific time point, with lower 
scores indicating better health
b The FIB-4 score is derived from age, and platelets, aspartate and alanine transaminase values
c Serious mental illness is defined as a medical history of at least one of the following diagnoses reported by the study investigator: major depres-
sion, anxiety, schizophrenia, bipolar disorder, post-traumatic stress disorder, or other psychosis
d The HIV-SI bothersome symptom count is a summation of the presence of the individual HIV-SI items and ranges from 0 to 20, with higher 
counts indicating more bothersome symptoms
e SF-36 PCS and MCS scores are normally distributed with a mean of 50 and a standard deviation of 10, with higher scores indicating better 
health










Age (years) 31 (18–71) 32 (18–68) 0.72 47 (21–71) 45 (20–70) 0.32
Male, n (%) 285 (90.8%) 282 (89.5%) 0.69 247 (87.6%) 252 (89.7%) 0.51
Race, n (%) 0.87 0.92
 White 180 (57.7%) 179 (56.8%) 206 (73.0%) 202 (72.7%)
 Non-white 132 (42.3%) 136 (43.2%) 76 (27.0%) 76 (27.3%)
Estimated GFR (mL/min) 126 (108–146) 123 (107–144) 0.76 101 (85–119) 101 (85–122) 0.73
VACS Index  scorea 17 (13–24) 14 (13–23) 0.34 12 (0–18) 10 (0–18) 0.19
CD4 cell count (cells/µL) 443 (299–590) 450 (324–608) 0.22 732 (554–936) 661 (478–874) 0.011
FIB-4 Index  scoreb 0.8 (0.6–1.1) 0.7 (0.6–1.1) 0.75 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.78
Asymptomatic, n (%) 286 (91.1%) 286 (90.8%) 1.00 243 (86.2%) 245 (87.2%) 0.80
Serious mental  illnessc, n (%) 91 (29.0%) 90 (28.6%) 0.93 122 (43.3%) 112 (39.9%) 0.44
HIV-SI symptom  countd 4.0 (1.0–7.0) 3.0 (1.0–7.0) 0.44 3.0 (1.0–6.5) 3.0 (1.0–5.0) 0.48
Years since HIV diagnosis 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.49 8.0 (4.0–13.0) 7.0 (3.0–14.0) 0.64
SF-36  PCSe 57.4 (52.6–60.0) 56.6 (52.2–59.3) 0.18 55.5 (50.5–59.1) 56.6 (51.0–59.2) 0.31
SF-36  MCSe 49.0 (37.7–55.2) 49.5 (40.0–56.3) 0.40 51.9 (44.5–57.5) 53.2 (46.6–57.6) 0.14
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3.3  Associations Between HIV‑SI Bothersome 
Symptoms and Treatment in Logistic Regression 
Models and Longitudinal Analyses
The association between treatment and each bothersome 
symptom from the HIV-SI was examined by logistic regres-
sion models and longitudinal analyses. In the final models, 
treatment group (B/F/TAF vs ABC/DTG/3TC) was the 
independent variable and covariates included age, sex, race 
(White vs non-White), baseline bothersome symptom count, 
VACS Index score, medical history of serious mental illness 
(yes vs no), baseline SF-36 PCS, baseline SF-36 MCS, and 
years since HIV diagnosis (for the suppressed study only).
In treatment-naive participants, the adjusted logistic 
regression models showed that B/F/TAF was associated with 
a lower risk of experiencing four bothersome symptoms at 
two or more time points (three symptoms included week 
48): fatigue/loss of energy, dizzy/lightheadedness, nausea/
vomiting, and difficulty sleeping. In virologically suppressed 
adults, the adjusted logistic regression models showed that 
B/F/TAF was associated with a lower risk of experiencing 
three symptoms at two or more time points (all symptoms 
included week 48): nausea/vomiting, sad/down/depressed, 
and nervous/anxious. A complete table of the unadjusted and 
adjusted logistic regression models appears as Table ESM1 
in the Electronic Supplementary Material.
The prevalence of bothersome symptoms over time was 
evaluated using mixed-effects logistic models adjusted for 
the same covariates as specified above and also included 
time and time-by-treatment in the model. In treatment-
naïve adults, the adjusted longitudinal models revealed a 
statistically significant difference in the prevalence of three 
bothersome symptoms (fatigue/loss of energy, nausea/vom-
iting, and loss of appetite) between the B/F/TAF and ABC/
Table 2  Frequency of bothersome HIV symptoms by treatment and study visit in Study GS-US-380-1489 (treatment-naïve)
n is the number of participants with response for at least one symptom
Bold characters are for significantly different percentages between treatment groups (p < 0.05), p value is calculated from the unadjusted logistic 
regression model





















Fatigue/loss of energy 47.3 46.6 37.7 47.1 33.6 41.7 32.8 41.4
Fevers/chills/sweats 26.7 21.7 20.4 18.7 14.0 15.5 15.4 14.8
Dizzy/lightheadedness 21.3 17.7 17.6 23.5 15.0 17.6 13.0 21.5
Pain/numbness/tingling 
in hands/feet
20.3 16.0 14.7 16.8 16.4 17.5 19.1 19.6
Trouble remembering 22.8 18.0 20.1 19.0 23.8 20.4 20.8 21.5
Nausea/vomiting 8.4 8.0 13.7 23.9 7.5 15.6 9.6 12.4
Diarrhea/loose bowels 20.9 18.9 20.8 21.3 15.6 18.8 11.6 14.8
Sad/down/depressed 41.9 36.5 31.9 35.5 33.2 32.4 27.6 31.3
Nervous/anxious 45.3 38.0 31.9 32.9 27.8 30.1 28.8 30.2
Difficulty sleeping 35.8 39.6 32.9 35.8 29.1 38.2 29.4 36.2
Skin problems/rash/
itching
27.3 28.5 21.7 25.8 19.5 22.3 20.8 22.1
Coughing/trouble 
breathing
15.4 15.4 13.4 14.0 14.4 13.9 12.7 14.1
Headaches 21.9 21.2 20.8 22.7 18.6 21.0 13.0 22.9
Loss of appetite 16.8 14.8 13.4 16.6 10.5 18.1 9.6 12.8
Bloating/pain/gas in 
stomach
19.7 21.0 24.4 24.4 20.3 22.0 18.5 25.3
Muscle aches/joint pain 27.1 28.3 19.2 21.1 23.6 22.3 21.6 25.3
Problems with sex 26.1 26.4 18.6 17.2 18.0 16.2 17.5 18.9
Changes in body com-
position
17.4 15.2 14.7 12.3 17.4 15.2 19.5 22.9
Weight loss/wasting 18.3 11.3 9.6 9.4 7.2 11.4 11.6 11.4
Hair loss/changes 10.3 12.9 6.7 9.4 6.9 8.4 5.5 8.8
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DTG/3TC groups over time, all favoring the B/F/TAF group. 
Three additional symptoms also showed that the effect over 
time was dependent on treatment group. These were head-
aches, bloating/pain/gas in stomach, and changes in body 
composition, each with lower prevalence over 48 weeks 
for B/F/TAF. In virologically suppressed participants, the 
adjusted longitudinal models revealed a statistically signifi-
cant difference between treatments over time (favoring B/F/
TAF over ABC/DTG/3TC) in the prevalence of six symp-
toms: dizzy/lightheadedness, nausea/vomiting, sad/down/
depressed, nervous/anxious, difficulty sleeping, and loss of 
appetite. No symptom favored the ABC/DTG/3TC group.
No covariate was significant in all symptom models; how-
ever, the presence of the bothersome symptoms at baseline, 
the HIV-SI symptom count at baseline, and SF-36 PCS score 
at baseline were significant for most symptom models. Each 
covariate was significant in at least one model. A complete 
table showing the coefficients, including findings for main 
effects and time by treatment interactions is provided in 
Table ESM2 of the Electronic Supplementary Material.
Tables 4 and 5 summarize the results for symptoms with 
statistically significant findings in the regression and/or lon-
gitudinal analyses. Fig. 1a and b show the observed preva-
lence of each symptom from Table 3 over time by treatment 
group that was statistically significantly different at two or 
more time points in the adjusted logistic regression model 
or at one time point in the adjusted logistic regression model 
and in the longitudinal model.
For treatment-naïve adults, the proportion of participants 
with poor sleep quality according to the PSQI was numeri-
cally less for B/F/TAF than AB/DTG/3TC at all postbase-
line time points, with a significantly significant difference 
noted at week 12 (favoring B/F/TAF) in the adjusted logistic 
regression model. For virologically suppressed participants, 
Table 3  Frequency of bothersome HIV symptoms by treatment and study visit in Study GS-US-380-1844 (HIV-1 suppressed)
n is the number of participants with response for at least one symptom
Bold characters are for significantly different percentages between treatment groups (p < 0.05), p value is calculated from the unadjusted logistic 
regression model





















Fatigue/loss of energy 38.6 35.6 30.7 35.7 35.7 36.5 34.6 38.3
Fevers/chills/sweats 14.4 10.7 12.9 8.9 14.7 14.5 10.5 11.7
Dizzy/lightheadedness 16.2 11.1 10.0 13.9 14.4 16.2 12.0 14.3
Pain/numbness/tingling 
in hands/feet
24.1 24.3 17.8 20.4 20.3 23.2 21.9 25.9
Trouble remembering 22.7 22.1 21.1 16.4 22.3 25.0 24.4 23.3
Nausea/vomiting 7.2 8.2 6.4 7.5 4.0 7.9 4.5 8.6
Diarrhea/loose bowels 16.5 15.7 15.0 16.8 15.8 16.3 11.7 13.9
Sad/down/depressed 28.9 25.3 19.6 22.9 22.7 26.0 23.0 30.9
Nervous/anxious 26.8 25.6 17.9 20.7 20.1 25.1 23.4 28.6
Difficulty sleeping 37.1 35.5 32.7 33.9 31.3 38.8 32.0 35.3
Skin problems/rash/
itching
21.2 15.7 14.6 14.6 17.7 20.3 22.6 21.5
Coughing/trouble 
breathing
16.8 13.7 13.6 12.9 13.7 11.9 15.9 17.8
Headaches 21.9 16.5 17.9 17.6 17.3 18.3 18.1 16.7
Loss of appetite 10.4 6.5 6.8 8.6 5.4 10.9 6.4 8.3
Bloating/pain/gas in 
stomach
22.7 23.5 20.8 24.4 17.3 21.9 19.3 19.4
Muscle aches/joint pain 30.4 28.5 22.9 22.9 30.0 28.5 28.3 25.2
Problems with sex 20.4 23.9 16.5 14.0 18.1 20.9 20.4 21.6
Changes in body com-
position
26.6 24.5 19.6 18.6 22.7 22.7 28.7 22.0
Weight loss/wasting 12.2 7.9 7.2 5.7 11.2 9.0 10.6 6.4
Hair loss/changes 7.9 6.9 7.5 3.2 4.3 6.5 9.4 9.1
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a significant treatment difference was noted at weeks 4 and 
12 in the adjusted logistic regression model as well as in 
the longitudinal model (all favoring B/F/TAF). Results from 
the PSQI are shown in Tables 4 and 5 as well as plotted in 
Fig. 1b.
4  Discussion
Our analyses represent the first prospective, randomized, 
double-blind comparison of patient-reported symptoms 
among HIV-1-infected adults who were either treatment 
naïve or virologically suppressed and randomized to receive 
B/F/TAF versus ABC/DTG/3TC. The results indicate that 
B/F/TAF was associated with fewer patient-reported bother-
some symptoms over 48 weeks, including nausea and some 
neuropsychiatric symptoms.
Descriptive analyses showed that differences between 
B/F/TAF and ABC/DTG/3TC appeared as early as week 4 
and were generally maintained through 48 weeks. In treat-
ment-naïve participants, the greatest differences between 
the two treatment groups were seen in reports of nausea/
vomiting, difficulty sleeping, fatigue/loss of energy, and 
dizzy/lightheadedness (Table 4). In virologically suppressed 
adults, nausea/vomiting and difficulty sleeping were again 
observed to be reported by a significantly greater propor-
tion of those receiving ABC/DTG/3TC, as were the symp-
toms of feeling sad/down/depressed and nervous/anxious 
(Table 5). Sleep findings on the HIV-SI were supported by 
findings of poor sleep quality on the PSQI. Both unadjusted/
adjusted and longitudinal analyses were reported here, since 
unadjusted/adjusted logistic regression models at fixed time 
points are useful for assessing treatment differences at the 
first postbaseline visit (week 4) and at the primary analysis 
time point (week 48), while the longitudinal model aims 
to assess treatment differences over time. This provides a 
collective assessment of all of the time points, using the 
individual’s responses at all time points (and the associated 
variability) to provide a singular assessment. The longitu-
dinal analysis has the advantage of distilling the numerous 
time points into a single value, albeit from a more compli-
cated model. As both the fixed time point and the longitu-
dinal analyses seek to answer different (but related) ques-
tions, they both provide insights into the data. As shown in 
Table 4  Summary of results from adjusted logistic regression analyses at weeks 4, 12, and 48 and longitudinal analyses in Study GS-US-380-
1489 (treatment-naïve)
ABC/DTG/3TC co-formulated abacavir, dolutegravir, and lamivudine, B/F/TAF co-formulated bictegravir, emtricitabine, and tenofovir alafena-
mide, HIV-SI HIV Symptom Index, PSQI Pittsburgh Sleep Quality Index
✓ = Statistically significant favoring the B/F/TAF group; ‡ = statistically significant time-by-treatment interaction (i.e., changes over time depend 
on treatment)
HIV-SI bothersome symptom Week 4 Week 12 Week 48 Longi-
tudinal 
model
Description of longitudinal findings
Fatigue/loss of energy ✓ ✓ ✓ ✓ Decreased prevalence in B/F/TAF group maintained over study 
period without any changes in prevalence from week 4 to week 48 
for either group
Dizzy/lightheadedness ✓ ✓ Decreased prevalence in B/F/TAF group, ABC/DTG/3TC group with 
fluctuating prevalence
Nausea/vomiting ✓ ✓ ✓ Increased initial prevalence in ABC/DTG/3TC group (at week 4) 
maintained over study period with decreasing prevalence in both 
groups from week 4 to week 48
Difficulty sleeping ✓ ✓ No differences in prevalence observed between groups from week 4 
to week 48
Headaches ✓ ‡ Decreased prevalence in B/F/TAF group from week 4 to week 48
Loss of appetite ✓ ✓ Decreased prevalence in B/F/TAF group, ABC/DTG/3TC group with 
fluctuating prevalence
Bloating/pain/gas in stomach ✓ ‡ No differences in prevalence observed between groups from week 4 
to week 48
Changes in body composition ‡ Slight increased prevalence in B/F/TAF group and a greater 
increased prevalence in ABC/DTG/3TC group
Weight loss/wasting ✓ No differences in prevalence observed between groups from week 4 
to week 48
Poor sleep quality (from PSQI) ✓ Decreased prevalence in B/F/TAF group starting from week 4 and 
maintained over study period with minimal changes in ABC/
DTG/3TC group
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Tables 4 and 5, some symptoms may be significant using 
fixed time-point models, but not in the longitudinal model. 
This is expected as the longitudinal model looks across all 
time points. A marginal finding at a single time point may 
not be significant when considering all time points. Impor-
tantly, no models showed significant treatment differences in 
the longitudinal model without at least one fixed time-point 
model showing significance as well. However, it should be 
noted that there were no large difference in PCS and MCS, 
aggregate measures from the SF-36, over time for either 
regimen.
The use of PRO tools within these studies provides 
insight into patient-reported symptoms that may be underre-
ported by individuals during standard screening for adverse 
drug events [38]. Others have suggested increasing the use 
of PRO tools in clinical research in order to differentiate in 
greater detail the benefit of various regimens [31, 39, 40]. 
Additionally, the use of longitudinal modeling allows for a 
greater understanding of the prevalence of HIV symptoms 
over time.
As the efficacy of well tolerated antiretroviral FDC regi-
mens in clinical trials reaches above 90%, it is important to 
demonstrate the comparative impact of various FDC options 
on HRQL measures and the degree to which they are per-
ceived by the individual as being bothersome. Tolerability 
and acceptance of long-term medication affect adherence to 
and persistence with that therapy. Adherence to antiretroviral 
treatments has been shown to improve outcomes and lower 
healthcare costs. Results from a real-world database analy-
sis found that individuals who were 95% or more adher-
ent to therapy had lower hospitalization rates and associ-
ated healthcare costs compared with those who had lower 
adherence rates [41]. Similarly, increased cost has been 
associated with adverse events. Among 11 adverse events 
(rash, nausea or vomiting, diarrhea, dizziness, headache, 
sleep-related symptoms, hepatotoxicity, lipid disorders, 
Table 5  Summary of results from adjusted logistic regression analyses at weeks 4, 12, and 48 and longitudinal analyses in Study GS-US-380-
1844 (HIV-1 suppressed)
ABC/DTG/3TC co-formulated abacavir, dolutegravir, and lamivudine, B/F/TAF co-formulated bictegravir, emtricitabine, and tenofovir alafena-
mide, HIV-SI HIV Symptom Index, PSQI Pittsburgh Sleep Quality Index
 ✓ = Statistically significant favoring the B/F/TAF group; ✗ = statistically significant favoring the ABC/DTG/3TC group
HIV-SI bothersome symptom Week 4 Week 12 Week 48 Longi-
tudinal 
model
Description of longitudinal findings
Fatigue/loss of energy ✓ No differences in prevalence observed between groups from 
week 4 to week 48
Dizzy/lightheadedness ✓ ✓ Decreased prevalence in B/FTC/TAF group at week 4 sustained 
through week 48, some increase in prevalence for ABC/
DTG/3TC group from week 4 to week 48
Pain/numbness/tingling in hands/feet ✓ No differences in prevalence observed between groups from 
week 4 to week 48
Nausea/vomiting ✓ ✓ ✓ Decreased prevalence in B/F/TAF group starting from week 4 
and maintained over study period with minimal changes in 
ABC/DTG/3TC group
Sad/down/depressed ✓ ✓ ✓ Decreased prevalence in B/F/TAF group starting from week 4 
and maintained over study period vs increased prevalence in 
ABC/DTG/3TC from week 4 to week 48
Nervous/anxious ✓ ✓ ✓ ✓ Decreased prevalence starting from week 4 and maintained 
over study period in B/F/TAF group vs fluctuating prevalence 
in ABC/DTG/3TC group
Difficulty sleeping ✓ ✓ Decreased prevalence in B/F/TAF group maintained over study 
period vs fluctuating prevalence in ABC/DTG/3TC group
Loss of appetite ✓ ✓ Decreased prevalence starting from week 4 in B/F/TAF group 
maintained over study period vs fluctuating prevalence in 
ABC/DTG/3TC group
Bloating/pain/gas in stomach ✓ No differences in prevalence observed between groups from 
week 4 to week 48
Hair loss/changes ✗ No differences in prevalence observed between groups from 
week 4 to week 48
Poor sleep quality (from PSQI) ✓ ✓ ✓ Decreased prevalence in B/F/TAF group starting from week 4 
and maintained over study period with minimal changes in 
ABC/DTG/3TC group
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depression, anxiety, and suicide or self-injury) observed 
with NRTI use, sleep-related adverse events had the high-
est outpatient care cost, with a mean per-episode cost of 
US$6438 (IQR 615–5882; median US$1785). Over a 5-year 
time period, sleep-related adverse events accounted for the 
second highest overall mean healthcare cost of US$8307, 
with only nausea and vomiting exceeding it with US$12,833 
[42].
There are limitations to this analysis that should be con-
sidered. While the results of the two studies are generalizable 
Fig. 1  a Prevalence of bothersome symptoms over time by treatment group in Study GS-US-380-1489 (Treatment-Naïve). b Prevalence of both-
ersome symptoms over time by treatment group in Study GS-US-380-1844 (HIV-1 Suppressed)
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to a broad patient population as both treatment-naïve and 
virologically suppressed adults were evaluated, they may 
not be generalizable to those who are not White males as 
the majority of the study participants were male and White. 
Furthermore, unlike investigator-reported symptoms, those 
reported by study participants are not graded using a stand-
ard scheme. Therefore, the severity of participant-reported 
symptoms may not be clear. However, the Likert scale did 
provide a sense of the degree to which a symptom was con-
sidered bothersome. Arguably, any symptom perceived to be 
bothersome to any extent is undesirable. Lastly, generaliz-
ability of study findings must be done with caution as the 
current study populations were relatively healthy with few 
co-morbidities; those who switched to B/F/TAF were stably 
suppressed with no tolerability issues to their antiretroviral 
therapy at baseline.
5  Conclusions
Overall, these studies demonstrated that over approximately 
1 year of follow-up after initiating or switching antiretroviral 
treatments, B/F/TAF was associated with fewer bothersome 
symptoms, especially nausea and vomiting, as well as sleep 
difficulties, than with ABC/DTG/3TC. Patient-reported 
symptoms may be an important consideration when select-
ing among highly efficacious options for the treatment of 
HIV infection and should continue to be studied in clinical 
trials.
Data Availability Statement The datasets generated during 
and/or analyzed during the current study are not publicly 
available due to the fact that they are proprietary intellectual 
property of the Sponsor (Gilead Sciences), but are available 
from the corresponding author on reasonable request.
Acknowledgements Dr. Wohl contributed to the acquisition of the data 
and manuscript preparation. Dr. Clarke contributed to the acquisition 
of the data and manuscript preparation. Dr. Maggiolo contributed to 
the acquisition of the data and manuscript preparation. Dr. Garner con-
tributed to the acquisition of data, analysis and interpretation of data, 
and manuscript preparation. Dr. Laouri contributed to the interpreta-
tion of data and the manuscript preparation. Dr. Martin contributed 
to the acquisition of the data and manuscript preparation. Dr. Quirk 
contributed to the acquisition of the data and manuscript preparation. 
We would like to thank Dr. Xuelian Wei and Dr. Hui Liu (both Gilead) 
for providing additional data analyses and interpretation, and Anna 
Kido (Gilead) for providing editorial assistance.
Compliance with Ethical Standards 
Potential Conflicts of Interest and Sources of Funding: Dr Wohl has 
served on advisory boards for Gilead and Janssen, and has received 
research grants to the University of North Carolina from Gilead. Dr 
Clarke has served on advisory boards for GSK and Gilead, and has 
received conference attendance support from Janssen, BMS and Gilead, 
and received a speaker fee from Gilead. Dr Maggiolo has served on 
advisory boards for Abbvie, Bristol-Myers Squibb, Gilead, GlaxoS-
mithKline, Tibotec, and has received research grants to ASST Papa 
Giovanni XXIII from Abbvie, Bristol-Myers Squibb, Gilead, Glaxo-
SmithKline, and Janssen. Drs Garner, Laouri, Martin, and Quirk are 
employees of Gilead Sciences and hold stock options in the company.
This study was funded by Gilead Sciences. This study was conducted 
in accordance with the Declaration of Helsinki. The protocol was re-
viewed and approved by central or site-specific institutional review 
boards or ethics committees covering all participating sites. All par-
ticipants provided written informed consent.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant 
JE, et al. Antiretroviral drugs for treatment and prevention of HIV 
infection in adults: 2016 recommendations of the international 
antiviral society-USA panel. JAMA. 2016;316:191–210.
 2. European AIDS Clinical Society. Guidelines. Version 9.0. October 
2017. Brussels: European AIDS Clinical Society, 2017. www.
eacso ciety .org/files /guide lines _9.0-engli sh.pdf. Accessed 30 May 
2018.
 3. Panel on Antiretroviral Guidelines for Adults and Adolescents. 
Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents: U. S. Department of Health and Human 
Services, Washington D.C., USA. https ://aidsi nfo.nih.gov/conte 
ntfil es/lvgui delin es/adult andad olesc entgl .pdf. Last Updated 27 
March 2018. Accessed 30 May 2018.
 4. Blanco J, Montaner JSG, Matconi VC, et al. Lower prevalence of 
drug resistance mutations at first-line virological failure to first-
line therapy with atripla vs. tenpfovir + emtricitabine/lamivu-
dine + efavirenz administered on a multiple tablet therapy. AIDS. 
2015;28:2531–9.
 5. Elliot E, Chirwa M, Boffito M. How recent findings on the phar-
macokinetics and pharmacodynamics of integrase inhibitors can 
inform clinical use. Curr Opin Infect Dis. 2017;30:58–73.
 6. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus 
tenofovir/emtricitabine as part of combination regimens for initial 
treatment of HIV: final results. J Infect Dis. 2011;204:1191–201.
 7. Quercia R, Roberts J, Murungi A, Curtis L, Payvandi N, Koteff J, 
Aboud M. Psychiatric adverse events from the DTG ART-naive 
phase III/IIIb clinical trials. HIV Glasgow 2016 Poster P210.
 8. Hsu R, Fusco J, Henegar C, Carpio F, Mounzer K, Wohlfeiler 
M, Vannappagari V, Aboud M, Curtis L, Fusco G. Psychiatric 
disorders observed in HIV + patients using 6 common 3rd agents 
in OPERA. In: Conference on Retroviruses and Opportunistic 
Infections CROI. Seattle 2017 Feb 13. http://www.natap .org/2017/
CROI/croi_62.htm. Accessed 25 Oct 2017.
 9. Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink 
HJ, Wyen C. Higher rates of neuropsychiatric adverse events lead-
ing to dolutegravir discontinuation in women and older patients. 
HIV Med. 2017;18:56–63.
 10. Llibre JM, Esteve A, Miro JP, Mateo G, Curran A, Podzamczer 
D. Discontinuation of DTG, EVG/c, and RAL due to toxicity in 
572 D. Wohl et al.
a prospective cohort. In: Conference on retroviruses and oppor-
tunistic infections CROI. Seattle 2017 Feb 13. http://www.natap 
.org/2017/CROI/croi_59.htm. Accessed 25 Oct 2017.
 11. Yagura H, Watanabe D, Nakauchi T, Tomishima K, Kasai D, 
Nishida Y. Effect of Dolutegravir plasma concentration on cen-
tral nervous system side effect. In: Conference on retroviruses and 
opportunistic infections CROI. Seattle 2017. http://www.natap 
.org/2017/CROI/croi_85.htm. Accessed 25 Oct 2017.
 12. Viswanathan P, Baro E, Soon G, Sherwat A, Struble K. Neuropsy-
chiatric adverse events associated with integrase strand transfer 
inhibitors. In: Conference on retroviruses and opportunistic infec-
tions CROI. Seattle 2017. http://www.natap .org/2017/CROI/
croi_60.htm. Accessed 25 Oct 2017.
 13. Wohl D, Mills A, Mera R, Pionkowsky D. Selected CNS outcomes 
among INSTI antiretrovirals. ID Week 2017 Abstract #1687.
 14. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bict-
egravir (GS-9883), a novel potent HIV-1 integrase strand transfer 
inhibitor with an improved resistance profile. Antimicrob Agents 
Chemother. 2016;60:7086–97.
 15. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, 
and tenofovir alafenamide versus dolutegravir, abacavir, and lami-
vudine for initial treatment of HIV-1 infection (GS-US-380-1489): 
a double-blind, multicentre, phase 3, randomised controlled non-
inferiority trial. Lancet. 2017;390:2063–72.
 16. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegra-
vir, emtricitabine, and tenofovir alafenamide versus dolutegravir 
with emtricitabine and tenofovir alafenamide, for initial treat-
ment of HIV-1 infection (GS-US-380-1490): a randomised, 
double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 
2017;S0140–6736(17):32340–1.
 17. Molina J-M, Ward DA, Brar I, et al. Switching to fixed-dose bicte-
gravir, emtricitabine, and tenofovir alafenamide from dolutegravir 
plus abacavir and lamivudine in virologically suppressed HIV-1 
infected adults: a randomised, double-blinded, multicentre, active-
controlled, phase 3, non-inferiority trial. Lancet HIV. 2018. https 
://doi.org/10.1016/S2352 -3018(18)30092 -4.
 18. Daar ES, DeJesus E, Ruane P, et al. Switching to fixed-dose bict-
egravir, emtricitabine, and tenofovir alafenamide from boosted 
protease inhibitor-based regimens in virologically suppressed 
HIV-1 infected adults: a randomised, open-label, multicentre, 
active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018. 
(In press).
 19. Elion RA, Althoff KN, Zhang J, et  al. Recent abacavir use 
increases risk of type 1 and type 2 myocardial infarctions among 
adults with HIV. J Acquir Immune Defic Syndr. 2018;78:62–72.
 20. Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir 
and risk of cardiovascular disease among HIV-infected individu-
als. J Acquir Immune Defic Syndr. 2016;71:413–9.
 21. Sabin CA, Reiss P, Ryom L. D:A:D Study Group. Is there con-
tinued evidence for an association between abacavir usage and 
myocardial infarction risk in individuals with HIV? a cohort col-
laboration. BMC Med. 2016;14:61.
 22. de Boer MG, van den Ber GE, van Holten N, et al. Intolerance of 
dolutegravir-containing combination antiretroviral therapy regi-
mens in real-life clinical practice. AIDS. 2016;30:2831–4.
 23. Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symp-
toms in patients receiving dolutegravir. J Acquir Defic Syndr. 
2017;74:423–31.
 24. Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus 
tenofovir disoproxil fumarate for the treatment of HBeAg-positive 
chronic hepatitis B virus infection: a randomised, double-blind, 
phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 
2016;1:185–95.
 25. Scott LJ, Chan HLY. Tenofovir alafenamide: a review in chronic 
hepatitis B. Drugs. 2017;77:1017–28.
 26. European Medicines Agency. Triumeq (dolutegravir, abacavir, 
lamivudine). Summary of product characteristics. 2018. http://
www.ema.europ a.eu/docs/en_GB/docum ent_libra ry/EPAR_-_
Produ ct_Infor matio n/human /00275 4/WC500 17559 6.pdf. 
Accessed 30 Mar 2018.
 27. Wu AW. Quality of life assessment comes of age in the era of 
highly active antiretroviral therapy. AIDS. 2000;14:1449–51.
 28. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the 
veterans aging cohort study index for mortality with HIV infec-
tion: a North American cross cohort analysis. J Acquir Immune 
Defic Syndr. 2013;62:149–63.
 29. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple 
noninvasive index to predict significant fibrosis in patients with 
HIV/HCV coinfection. Hepatology. 2006;43:1317–25.
 30. Justice A, Holmes W, Gifford A, et al. Development and valida-
tion of a self-completed HIV symptom index. J Clin Epidemiol. 
2001;2001(54):S77–90.
 31. Simpson KN, Hanson KA, Harding G, Haider S, Tawadrous M, 
Khachatryan A, et al. Patient reported outcome instruments used 
in clinical trials of HIV-infected adults on NNRTI-based therapy: 
a 10-year review. Health Qual Life Outcomes. 2013;11:164.
 32. Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC, 
Vacs Project T. Patient-reported symptoms on the antiretroviral 
regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care 
STDS. 2012;26:312–9.
 33. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health 
survey questionnaire: new outcome measure for primary care. 
BMJ. 1992;305:160–4.
 34. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health 
survey (SF-36). I. Conceptual framework and item selection. Med 
Care. 1992;30:473–83.
 35. Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD. Compari-
son of WHOQOL-bREF and SF-36 in patients with HIV infection. 
Qual Life Res. 2005;14:141–50.
 36. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. 
The Pittsburgh Sleep Quality Index: a new instrument for psychi-
atric practice and research. Psychiatry Res. 1989;28:193–213.
 37. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproduc-
ibility of a work productivity and activity impairment instrument. 
Pharmacoeconomics. 1993;4:353–65.
 38. Edelman EJ, Gordon K, Justice AC. Patient and provider-reported 
symptoms in the post-cART era. AIDS Behav. 2011;15:853–61.
 39. Kozak MS, Mugavero MJ, Ye J, et al. Patient reported outcomes 
in routine care: advancing data capture for HIV cohort research. 
Clin Infect Dis. 2012;2012(54):141–7.
 40. Engler K, Lessard D, Lebouche B. A review of HIV-specific 
patient-reported outcome measures. Patient. 2017;10:187–202.
 41. Cohen CJ, Meyers JL, Davis KL. Association between daily 
antiretroviral pill burden and treatment adherence, hospitalisation 
risk, and other healthcare utilisation and costs in a US medicaid 
population with HIV. BMJ Open. 2013;3:e003028.
 42. Boulanger L, Chambers R, Nedrow K, et al. Costs of adverse 
events among patients with HIV infection treated with nonnucleo-
side reverse transcriptase inhibitors. HIV Med. 2014;15:488–98.
573PROs After Initiating or Switching to B/F/TAF Versus ABC/DTG/3TC
Affiliations
David Wohl1 · Amanda Clarke2 · Franco Maggiolo3 · Will Garner4 · Marianne Laouri4 · Hal Martin4 · Erin Quirk4
 * Hal Martin 
 Hal.Martin@gilead.com
1 University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA
2 Royal Sussex County Hospital, Brighton, UK
3 ASST Papa Giovanni XXIII, Bergamo, Italy
4 Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, 
CA 94404, USA
